EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluating the Use of Sacran, a Polysaccharide Isolated from Aphanothece sacrum, as a Possible Microbicide for Preventing HIV-1 Infection

Kouki Matsuda iD, Ryusho Kariya, Kenji Maeda, Seiji Okada iD

Viruses · 2024

DOI: 10.3390/v16091501 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Kouki Matsuda und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto 860-0811, Japan. Hauptthemen laut MEDLINE: HIV-1, HIV Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Science and Technology Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since combination antiretroviral therapy (cART) was introduced to treat human immunodeficiency virus type-1 (HIV-1)/acquired immunodeficiency syndrome (AIDS), the AIDS mortality rate has markedly decreased, and convalescence in individuals with HIV has improved drastically. However, sexual transmission has made HIV-1 a global epidemic. Sacran is a megamolecular polysaccharide extracted from cyanobacterium Aphanothece sacrum that exhibits numerous desirable characteristics for transdermic applications, such as safety as a biomaterial, a high moisture retention effect, the ability to form a film and hydrogel, and an anti-inflammatory effect. In this study, we evaluated the anti-HIV-1 effects in sacran as a barrier to HIV-1 transmission. Sacran inhibited HIV-1 infection and envelope-dependent cell-to-cell fusion. Moreover, we used a Transwell assay to confirm that sacran inhibited viral diffusion and captured viruses. The synergistic effects of sacran and other anti-HIV infection drugs were also evaluated. HIV-1 infections can be reduced through the synergistic effects of sacran and anti-HIV-1 drugs. Our study suggests using sacran gel to provide protection against HIV-1 transmission.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV InfectionsHumansCyanobacteriaAnti-HIV AgentsPolysaccharides, BacterialPolysaccharidesAnti-Infective AgentsVirus InternalizationCell Line

Stichwörter der Autor:innen

HIV-1microbicidesacran

Substanzen

Anti-HIV AgentsPolysaccharides, BacterialPolysaccharidesAnti-Infective Agents

Autor:innen und Institutionen

  • Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto 860-0811, Japan.
  • Division of Antiviral Therapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima 890-8544, Japan.

ORCID-Profile: Kouki Matsuda, Seiji Okada

Förderung

  • Japan Science and Technology Agency

Zitieren

APA

Matsuda, K., Kariya, R., Maeda, K., & Okada, S. (2024). Evaluating the Use of Sacran, a Polysaccharide Isolated from Aphanothece sacrum, as a Possible Microbicide for Preventing HIV-1 Infection. Viruses. https://doi.org/10.3390/v16091501

Vancouver

Matsuda K, Kariya R, Maeda K, Okada S. Evaluating the Use of Sacran, a Polysaccharide Isolated from Aphanothece sacrum, as a Possible Microbicide for Preventing HIV-1 Infection. Viruses. 2024. doi:10.3390/v16091501

BibTeX
@article{Matsuda2024,
  author = {Matsuda, Kouki and Kariya, Ryusho and Maeda, Kenji and Okada, Seiji},
  title = {Evaluating the Use of Sacran, a Polysaccharide Isolated from Aphanothece sacrum, as a Possible Microbicide for Preventing HIV-1 Infection},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16091501}
}
Kostenlos starten →